Vol 71, No 5 (2020)
Clinical vignette
Published online: 2020-08-27
Regular chromogranin A monitoring facilitated the early detection of a gastrointestinal neuroendocrine tumour in a patient with type 1 diabetes
1
, 1, 1, 2, 3, 4, 5, 1
, 1, 1, 2, 3, 4, 5, 1
Abstract
Not required for Clinical Vignette.
Keywords: chromogranin Adiabetes mellitus type 1enterochromaffin-like cellsatrophic gastritisneuroendocrine tumours
References
- Wang R, Zheng-Pywell R, Chen HA, et al. Management of Gastrointestinal Neuroendocrine Tumors. Clin Med Insights Endocrinol Diabetes. 2019; 12: 1179551419884058.
- Herold Z, Doleschall M, Kovesdi A, et al. Chromogranin A and its role in the pathogenesis of diabetes mellitus. Endokrynol Pol. 2018; 69(5): 598–610.
- Herold Z, Herold M, Nagy P, et al. Serum chromogranin A level continuously rises with the progression of type 1 diabetes, and indicates the presence of both enterochromaffin-like cell hyperplasia and autoimmune gastritis. J Diabetes Investig. 2019 [Epub ahead of print].
- De Block CEM, Colpin G, Thielemans K, et al. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes. Diabetes Care. 2004; 27(6): 1387–1393.
- Bizzaro N, Antico A, Villalta D. Autoimmunity and Gastric Cancer. Int J Mol Sci. 2018; 19(2).
